Objective: To elucidate the degree of genetic polymorphisms CYP2C19 (CYP2C19* 2,
CYP2C19* 3) of key drug metabolizing enzymes on the antiplatelet effect of clopidogrel …

Recently published data indicate that CYP2C19* 2 allele is the major determinant of
metabolic bioactivation of clopidogrel and thereby variability of antiplatelet effect of …

CYP2C19 genetic polymorphisms influence clopidogrel response and clinical outcomes of
cardiovascular disease. However, data on their relationship in stroke patients are scarce …

Background: Variable response after clopidogrel is well documented and may affect major
adverse clinical events after stroke. Impact of CYP2C19 genetic polymorphisms is an …

Objectives This study sought to evaluate the influence of the genetic polymorphisms on
platelet reactivity and clinical outcomes in acute ischemic stroke patients taking clopidogrel …

Background and Purpose—Little research regarding genotypes and clopidogrel response
related to acute ischemic stroke has been published. This study was conducted to …

Background: CYP2C19 variants are associated with the antiplatelet effects of clopidogrel
against recurrent cardiovascular events. However, it remains unknown whether the elapsed …

Purpose Clopidogrel is a prodrug that requires transformation into an active metabolite by
cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine …

Clopidogrel is an inhibitor of platelet-aggregation used in the prevention of secondary
stroke. The molecule is activated by the cytochrome P450 2C19 (CYP2C19) enzyme. The …

Objectives To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy
comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its …